tiprankstipranks
Advertisement
Advertisement

MLTX Stock Latest News

MoonLake Secures Long-Term Manufacturing Capacity with Vetter Pharma
Company AnnouncementsMoonLake Secures Long-Term Manufacturing Capacity with Vetter Pharma
3d ago
8K
MLTX
MoonLake Immunotherapeutics: Buy Rating Reiterated on De-Risked Path to 2026 BLA and Robust SLK Data; $30 Price Target Maintained
PremiumRatings
MoonLake Immunotherapeutics: Buy Rating Reiterated on De-Risked Path to 2026 BLA and Robust SLK Data; $30 Price Target Maintained
23d ago
MLTX
Phil Nadeau Reiterates Buy on MoonLake Immunotherapeutics as Sonelokimab Advances Toward 2027 Launch with $3B+ Peak Sales Potential
PremiumRatings
Phil Nadeau Reiterates Buy on MoonLake Immunotherapeutics as Sonelokimab Advances Toward 2027 Launch with $3B+ Peak Sales Potential
24d ago
MLTX
MoonLake advances sonelokimab toward BLA after positive FDA meeting
PremiumCompany Announcements
MoonLake advances sonelokimab toward BLA after positive FDA meeting
24d ago
8K
MLTX
MoonLake price target raised to $45 from $40 at H.C. Wainwright
PremiumThe Fly
MoonLake price target raised to $45 from $40 at H.C. Wainwright
24d ago
MLTX
MoonLake FDA meeting yields ‘best-in-class’ label, says Clear Street
PremiumThe FlyMoonLake FDA meeting yields ‘best-in-class’ label, says Clear Street
24d ago
MLTX
MoonLake says aligned with FDA on submission plans for sonelokimab
Premium
The Fly
MoonLake says aligned with FDA on submission plans for sonelokimab
24d ago
MLTX
MoonLake Immunotherapeutics reports Q1 EPS -98c vs. -91c last year
Premium
The Fly
MoonLake Immunotherapeutics reports Q1 EPS -98c vs. -91c last year
24d ago
MLTX
Buy Rating on MoonLake: Sonelokimab’s Differentiated IL‑17 Profile and Late‑Stage HS Opportunity Support $40 Target
PremiumRatings
Buy Rating on MoonLake: Sonelokimab’s Differentiated IL‑17 Profile and Late‑Stage HS Opportunity Support $40 Target
2M ago
MLTX
Positive Risk-Reward and Strategic Momentum Underpin Buy Rating on MoonLake Immunotherapeutics
PremiumRatings
Positive Risk-Reward and Strategic Momentum Underpin Buy Rating on MoonLake Immunotherapeutics
2M ago
MLTX
MoonLake Buy Rating: Clear HS Approval Path, Priority Review Upside, and Underappreciated Multi-Indication Value
PremiumRatings
MoonLake Buy Rating: Clear HS Approval Path, Priority Review Upside, and Underappreciated Multi-Indication Value
2M ago
MLTX
MoonLake Immunotherapeutics announces results from Phase 3 VELA-1, VELA-2 trial
PremiumThe Fly
MoonLake Immunotherapeutics announces results from Phase 3 VELA-1, VELA-2 trial
2M ago
MLTX
MoonLake Immunotherapeutics management to meet with BTIG
PremiumThe FlyMoonLake Immunotherapeutics management to meet with BTIG
2M ago
MLTX
MoonLake upgraded to Outperform from Underperform at Wolfe Research
Premium
The Fly
MoonLake upgraded to Outperform from Underperform at Wolfe Research
2M ago
MLTX
Micron downgraded, Five Below upgraded: Wall Street’s top analyst calls
Premium
The Fly
Micron downgraded, Five Below upgraded: Wall Street’s top analyst calls
3M ago
MU
ADP
MoonLake upgraded to Buy from Neutral at Rothschild & Co Redburn
PremiumThe Fly
MoonLake upgraded to Buy from Neutral at Rothschild & Co Redburn
3M ago
MLTX
MoonLake Immunotherapeutics: Sonelokimab’s Differentiated IL‑17A/F Profile and Multibillion-Dollar Potential Underpin Buy Rating Despite HS Trial Concerns
PremiumRatings
MoonLake Immunotherapeutics: Sonelokimab’s Differentiated IL‑17A/F Profile and Multibillion-Dollar Potential Underpin Buy Rating Despite HS Trial Concerns
3M ago
MLTX
MoonLake price target raised to $70 from $45 at Clear Street
PremiumThe Fly
MoonLake price target raised to $70 from $45 at Clear Street
3M ago
MLTX
MoonLake Immunotherapeutics price target raised to $40 from $32 at H.C. Wainwright
PremiumThe Fly
MoonLake Immunotherapeutics price target raised to $40 from $32 at H.C. Wainwright
3M ago
MLTX
MoonLake Immunotherapeutics price target raised to $11 from $10 at Goldman Sachs
PremiumThe FlyMoonLake Immunotherapeutics price target raised to $11 from $10 at Goldman Sachs
3M ago
MLTX
MoonLake Immunotherapeutics price target raised to $35 from $30 at Oppenheimer
Premium
The Fly
MoonLake Immunotherapeutics price target raised to $35 from $30 at Oppenheimer
3M ago
MLTX
Sonelokimab: Strong HS and AxSpA Data, Clear Regulatory Path Support Best‑in‑Class Potential and Buy Rating
Premium
Ratings
Sonelokimab: Strong HS and AxSpA Data, Clear Regulatory Path Support Best‑in‑Class Potential and Buy Rating
3M ago
MLTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >